Why the study?
The mechanisms underlying platelet extracellular vesicle formation, including the role of purinergic receptors, remain an active research field despite increasing publications.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review summarizes the clinical relevance of platelet extracellular vesicles in cardiovascular disease and the role of P2Y receptors in their formation.
Platelet extracellular vesicles (PEVs) are potential new biomarkers of platelet activation which may allow us to predict and/or diagnose developing coronary thrombosis before myocardial necrosis occurs. The P2Y1 and P2Y12 receptors play a key role in platelet activation and aggregation. Whereas the P2Y1 antagonists are at the preclinical stage, at present, the P2Y12 antagonists are the most effective treatment strategy to prevent stent thrombosis after percutaneous coronary intervention. Despite an increasing number of publications on PEVs, the mechanisms underlying their formation, including the role of purinergic receptors in this process, remain an active research field. Here, we outline the clinical relevance of PEVs in cardiovascular disease, summarize the role and downstream signalling of P2Y receptors in platelet activation, and discuss the available evidence regarding their role in PEV formation.
No takes yet. Share an insight, caveat, or question.
Gąsecka et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: